IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma
Glioma is characterized by strong immunosuppression and excessive angiogenesis. Based on existing reports, it can be speculated that the resistance to anti-angiogenic drug vascular endothelial growth factor A (VEGFA) antibody correlates to the induction of novel immune checkpoint indoleamine 2,3-dio...
主要な著者: | , , , , , , , |
---|---|
フォーマット: | 論文 |
言語: | English |
出版事項: |
MDPI AG
2024-06-01
|
シリーズ: | Pharmaceutics |
主題: | |
オンライン・アクセス: | https://www.mdpi.com/1999-4923/16/7/870 |